17.48 0.00 (0.00%)
After hours: 6:23PM EDT
|Bid||17.48 x 800|
|Ask||17.59 x 2200|
|Day's range||17.44 - 17.91|
|52-week range||5.27 - 18.16|
|Beta (3Y Monthly)||0.08|
|PE ratio (TTM)||N/A|
|Earnings date||8 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.81|
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
PLC (ENDP) on Friday said its Endo Pharmaceuticals Inc. unit is recalling two lots of the muscle relaxant Robaxin due to incorrect dosing information on the label that could lead to overdose. Endo said patients who follow the incorrect directions could experience significant drowsiness or dizziness that would put them at risk for falls or an overdose that could result in seizures, coma or death. An Endo spokeswoman said the recall, which affects about 2,856 bottles of tablets, was voluntary and precautionary, and that the company hasn’t received any reports of injuries or serious adverse reactions related to the issue.
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
NEW YORK, Sept. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The Zacks Analyst Blog Highlights: Ingersoll-Rand, Endo International, Glanbia and Smurfit Kappa Group
Ireland's growth in the past few years not only shows its resilience to the economic downturn in the EU but also makes it one of the most business-friendly destinations of the region.
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jim Cramer zooms through his take on fans' favorite stocks in a special edition of the lightning round.
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Zacks.com highlights: Medifast, Endo International, HCA Healthcare, Five9 and FTI Consulting
RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRXRBC updates its view on the generic pharma industry
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.